Technology Bundle ID
TAB-2671

Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus

Linked ID
E-269-2013-0
Lead Inventors
Laura McMullan (CDC)
Co-Inventors
Aubree Kelly (CDC)
Cynthia Goldsmith (CDC)
Stuart Nichol (CDC)
William Nicholson (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early stage
  • In vitro data available
ICs
CDC
This CDC invention relates to primers and probes that specifically hybridize with Heartland virus (HRTLDV), a unique member of the genus Phlebovirus. It further relates to polyclonal antibodies specific for HRTLDV proteins. Serological detection assays using HRTLDV nucleic acid molecules, proteins, probes, primers, and antibodies are provided. Importantly, the HRTLDV genome can be engineered using reverse genetics to be attenuated, allowing development of a vaccine for other viruses within the Phlebovirus genus or Bunyaviridae family. Individual proteins or peptides of the HRTLDV can also be used in other FDA-approved virus backbones to act as vaccines. Further, since HRTLDV targets the bone marrow, disclosed HRTLDV delivery vehicles may be used to deliver therapeutic agents to the bone marrow.
Commercial Applications
  • Development of nucleic acid (RT-PCR) and serologic diagnostic assays for phleboviruses
  • Phlebovirus vaccines
  • Novel delivery vehicles for bone marrow-originating diseases
  • Research tool for phlebovirus virulence mechanisms
  • Vector or tick-borne illness monitoring programs for both humans and wildlife
Competitive Advantages
  • Antigens and antibodies for diagnostic use have been developed
  • RT-PCR allows rapid, quantitative diagnosis
  • Potential use as bone marrow therapeutic delivery tools
  • Recombinant, pseudo-phlebovirus reporter systems have potential for a wide range of high-throughput drug-screening and research applications

Request More Info

Licensing Contact: